GadoSpin D

Dynamic contrast-enhanced MRI agent

Order no:

GadoSpin D MRI contrast agent (1 x 5 injections): 130 - 095 - 164
GadoSpin D MRI contrast agent (5 x 5 injections): 130 - 095 - 165

Quantity
Unit
price per item:
480.00
Excluding VAT and shipping costs
Add to cart

GadoSpin D is a unique dendritic MRI agent for studying blood vessel integrity and angiogenesis in tumors and inflamed tissues via dynamic contrast-enhanced (DCE) MRI. It contains 24 gadolinium ions in a globular structure.

The unique dendritic MRI agent:

  • Has an intermediate molecular weight optimized for vascular studies
  • Stays confined within intact vasculature
  • Passes through fenestrated blood vessel in tumors and inflamed tissue
  • GadoSpin D is Viscover’s leading agent for dynamic contrast-enhanced (DCE) MRI imaging

Apply GadoSpin D to effectively:

  • Quantitate angiogenesis and investigate vascular abnormalities in tumors and inflammation with ease
  • Monitor therapeutic efficacy
  • Use its blood pool effect for MR angiography as an alternative to GadoSpin P
Physico-chemical properties and structure

Relaxivity (37 °C, 1.5T)

In plasma:

r1 = 19 L mmol-1 s-1
r2 = 29 L mmol-1 s-1

In water:

r1 = 17 L mmol-1 s-1
r2 = 22 L mmol-1 s-1

Molecular weight:

~17,000 g mol-1

Schematic diagram of GadoSpin D:

GadoSpin D dynamic contrast-enhanced imaging
DCE-MRI-based tumor therapy monitoring using GadoSpin D. The effect of anti- angiogenic treatment in mice is studied as contrast agent uptake in regions of tumor angiogenesis. Comparing T1-weighted pre- and post-contrast scans, the contrast effect appears to be significantly lower (and restricted to the cortex region) in treated mice as compared to control mice. This can be attributed to a treatment-induced reduction of neovasculature.
Schematic representation of DCE-MRI using GadoSpin D. Tumor tissue exhibits a significantly higher extravasation of the agent than the reference muscle tissue. Temporal sampling allows for exact quantification and calculation of exchange rate constants.
Left:
DCE-MRI-based tumor therapy monitoring using GadoSpin D. The effect of anti-angiogenic treatment in mice is studied as contrast agent uptake in regions of tumor angiogenesis. Comparing T1-weighted pre- and post-contrast scans, the contrast effect appears to be significantly lower (and restricted to the cortex region) in treated mice as compared to control mice. This can be attributed to a treatment-induced reduction of neovasculature.
Right:
Schematic representation of DCE-MRI using GadoSpin D. Tumor tissue exhibits a significantly higher extravasation of the agent than the reference muscle tissue. Temporal sampling allows for exact quantification and calculation of exchange rate constants.
Selected references
  1. Su, M.Y. et al. (2002) Measurements of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring. Technol. Cancer Res. Treat. 1: 479-488.
  2. Verhoye, M. et al. (2002) Assessment of the neovascular permeability in glioma xenografts by dynamic T(1) MRI with Gadomer-17. Magn. Reson. Med 47: 305-313.
  3. Fink, C. et al. (2003) High resolution three-dimensional MR angiography of rodent tumors: Morphologic characterization of intratumoral vasculature. J. Magn. Reson. Imaging 18: 59-65.
  4. Hamzah, J. et al. (2008) Vascular normalization in Rgs5-deficient tumors promotes immune destruction. Nature 453: 410-414.

 
Further information